



(12) Translation of
European patent specification

(11) NO/EP 2406371 B1

NORWAY

(19) NO
(51) Int Cl.
C12N 5/079 (2010.01)
C12Q 1/37 (2006.01)
G01N 33/50 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.10.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.05.09
(86)	European Application Nr.	10709359.3
(86)	European Filing Date	2010.03.12
(87)	The European Application's Publication Date	2012.01.18
(30)	Priority	2009.03.13, US, 160199 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	ALLERGAN, INC., 2525 Dupont Drive, Irvine, CA 92612, US-USA
(72)	Inventor	JACKY, Birgitte, P.S., 166 N. Waverly Street, OrangeCA 92866, US-USA WANG, Joanne, 37 Bristlecone, IrvineCA 92620, US-USA ZHU, Hong, 11408 Pacific Shores Way, San DiegoCA 92130, US-USA HODGES, D., Dianne, 14351 Pinewood Road, TustinCA 92780, US-USA FERNANDEZ-SALAS, Ester, 1710 Rocky Road, FullertonCA 92831, US-USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
(56)	References Cited:	WO-A1-2009/114748, MARINI PATRIZIA ET AL: "SiMa, a new neuroblastoma cell line combining poor prognostic cytogenetic markers with high adrenergic differentiation", CANCER GENETICS AND CYTOGENETICS, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 112, 1 January 1999 (1999-01-01), pages 161-164, XP003027695, ISSN: 0165-4608, ESTER FERNÁNDEZ-SALAS ET AL: "Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay", PLOS ONE, vol. 7, no. 11, 21 November 2012 (2012-11-21), page e49516, XP055070996, DOI: 10.1371/journal.pone.0049516, MASUMOTO N ET AL: "Involvement of SNAP-25 in TRH-induced exocytosis in pituitary GH4C1 cells" JOURNAL OF ENDOCRINOLOGY, vol. 153, no. 1, 1997, pages R5-R10, XP008124119 ISSN: 0022-0795, PELLETT SABINE ET AL: "A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies." FEBS LETTERS 16 OCT 2007 LNKD- PUBMED:17889852, vol. 581, no. 25, 16 October 2007 (2007-10-16), pages 4803-4808, XP22289797 ISSN: 0014-5793, YOWLER BRIAN C ET AL: "Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I." THE JOURNAL OF BIOLOGICAL CHEMISTRY 6 SEP 2002 LNKD- PUBMED:12089155, vol. 277, no. 36, 6 September 2002 (2002-09-06), pages 32815-32819, XP002590839 ISSN: 0021-9258

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

CELLER NYTTIGE FOR AKTIVITETSANALYSER FOR IMMUNO-BASERT BOTULINUMTOKSIN SEROTYPE A

Patentkrav

1. Celler fra en udødelig cellelinje valgt fra en parenteral SiMA-cellelinje DSMZ ACC 164, hvori cellene er mottakelige for BoNT/A-forgiftning og hvori cellene utviser en EC_{50} for BoNT/A-aktivitet av 2,2 pM eller mindre.